Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Intangibles (2017 - 2024)

Historic Intangibles for Innate Pharma (IPHA) over the last 8 years, with Q2 2024 value amounting to $128149.6.

  • Innate Pharma's Intangibles fell 8696.74% to $128149.6 in Q2 2024 from the same period last year, while for Jun 2024 it was $128149.6, marking a year-over-year decrease of 8696.74%. This contributed to the annual value of $449994.5 for FY2023, which is 7165.4% down from last year.
  • Per Innate Pharma's latest filing, its Intangibles stood at $128149.6 for Q2 2024, which was down 8696.74% from $447591.0 recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's Intangibles ranged from a high of $95.2 billion in Q2 2020 and a low of $128149.6 during Q2 2024
  • In the last 5 years, Innate Pharma's Intangibles had a median value of $46.2 million in 2022 and averaged $10.6 billion.
  • The largest annual percentage gain for Innate Pharma's Intangibles in the last 5 years was 839.92% (2021), contrasted with its biggest fall of 9994.28% (2021).
  • Over the past 5 years, Innate Pharma's Intangibles (Quarter) stood at $55.2 million in 2020, then fell by 8.4% to $50.6 million in 2021, then tumbled by 96.86% to $1.6 million in 2022, then crashed by 71.81% to $447591.0 in 2023, then crashed by 71.37% to $128149.6 in 2024.
  • Its last three reported values are $128149.6 in Q2 2024, $447591.0 for Q4 2023, and $983298.6 during Q2 2023.